6-Fluoro-3-hydroxypyrazine-2-carboxamide

Independent reference data for 6-Fluoro-3-hydroxypyrazine-2-carboxamide (CAS 259793-96-9), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

In 2014, favipiravir was approved in Japan to treat cases of influenza that were unresponsive to conventional treatment. Given its efficacy at targetting several strains of influenza, it has been investigated in other countries to treat novel viruses including Ebola and most recently, COVID-19.Breast Feeding; Lactation; Milk, Human; Antiviral Agents

Synonyms and trade names

Favipiravir; 259793-96-9; 6-FLUORO-3-HYDROXYPYRAZINE-2-CARBOXAMIDE; avigan; T-705; 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide; T 705; Fapilavir; EW5GL2X7E0; Favilavir; T-705 cpd; T705; DTXSID60948878; 2-Pyrazinecarboxamide, 6-fluoro-3-hydroxy-; CHEBI:134722

GHS hazard classification

Reported hazard statements	H302 (40%), H315 (60%), H319 (60%), H335 (60%), H341 (20%), H361 (40%)

H302 (40%): Harmful if swallowed [Warning Acute toxicity, oral]

H315 (60%): Causes skin irritation [Warning Skin corrosion/irritation]

What the public record says

6-Fluoro-3-hydroxypyrazine-2-carboxamide · CAS 259793-96-9 · C5H4FN3O2. UNII EW5GL2X7E0. Melting Point: 187℃ to 193℃; Dissociation Constants: 5.1.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.